The Role of Cyclic Nucleotides in the Release of Tissue-Type Plasminogen Activator and von Willebrand Factor

Summary

The modulation of the induced acute release of tissue-type plasminogen activator (t-PA) and of von Willebrand factor (vWF) by compounds affecting cyclic nucleotide levels was studied, using an isolated rat hindleg perfusion system. Platelet-activating factor (PAF; 5 nM) or bradykinin (0.8 (μM) were used to induce release of t-PA and vWF.

The guanylate cyclase activators sodium nitroprusside and atrial natriuretic factor reduced the induced release of t-PA and vWF. Release was not affected by inhibiting nitric oxide production with N^G-nitro-L-arginine. The effects of nitroprusside and atrial natriuretic factor could not be reproduced by infusion of 8-bromo-cGMP.

The adenylate cyclase activator forskolin had no effect on bradykinin-induced release of t-PA and vWF, reduced PAF-induced t-PA release, but potentiated PAF-induced vWF release. These modulatory effects were only partially mimicked by infusion of 8-bromo-cAMP.

None of the compounds tested was able to induce the release of t-PA or of vWF in the absence of stimulation by bradykinin or platelet-activating factor. Cyclic nucleotides can thus modulate, but not induce, the acute release of t-PA and vWF from perfused rat hindlegs.

• References

• 1 Tranquille N, Emeis JJ. The effect of Pentoxifylline (Trental) and two analogues, BL 194 and HWA 448, on the release of plasminogen activators and von Willebrand factor in rats. J Cardiovasc Pharmacol 1991; 18: 35-42
• 2 Stefanovitch V. Effect of 3,7-dimethyl-1-(5-oxohexyl)-xanthine on cyclic AMP phosphodiesterase of the human umbilical cord vessels. Res Comm Chem Pathol Pharmacol 1973; 5: 655-662
• 3 Korbut R, Lidbury PS, Vane JR. Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet 1990; 335: 669
• 4 Lidbury PS, Korbut R, Vane JR. Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br J Pharmacol 1990; 101: 527-530
• 5 Mannucci PM. Enhancement of plasminogen activator by vasopressin and adrenaline: a role of cAMP?. Thromb Res 1974; 4: 539-549
• 6 Tranquille N, Emeis JJ. Release of tissue-type plasminogen activator is induced in rats by leukotrienes C4 and D4, but not by prostaglandins E1, E2 and I2. Br J Pharmacol 1988; 93: 156-164
• 7 Tranquille N, Emeis JJ. The simultaneous acute release of tissue-type plasminogen activator and von Willebrand factor in the perfused rat hindleg region. Thromb Haemostas 1990; 63: 454-458
• 8 Verheijen JH, Mullart E, Chang GTG, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 9 Ingerslev J. A sensitive ELISA for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest 1987; 47: 143-149
• 10 Tranquille N, Emeis JJ. On the role of calcium in the acute release of tissue-type plasminogen activator and von Willebrand factor from the rat perfused hindleg region. Thromb Haemostas 1991; 66: 479-483
• 11 Martin W, White DG, Henderson AH. Endothelium-derived relaxing factor and atriopeptin II elevate cyclic GMP levels in pig aortic endothelial cells. Br J Pharmacol 1988; 93: 229-239
• 12 Schini V, Grant NJ, Miller RC. Takeda K. Morphological characterization of cultured bovine aortic endothelial cells and the effects of atriopeptin II and sodium nitroprusside on cellular and extracellular accumulation of cyclic GMP. Eur J Cell Biol 1988; 47: 53-61
• 13 Leitman DC, Andresen JW, Kuno T, Kamisaki Y, Chang JK, Murad F. Identification of multiple binding sites for atrial natriuretic factor by affinity cross-linking in cultured endothelial cells. J Biol Chem 1986; 261: 11650-11655
• 14 Moore PK, Alswayeh OA, Cheng NWS, Evans RA, Gibson A. L-N^G-Nitro Arginine (L-NOARG), a novel L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 1990; 99: 408-412
• 15 Laurenza A, McHugh Sutkowski E, Seamon KB. Forskolin: a specific stimulator of adenyl cyclase or a diterpene with multiple sites of action?. Trends Pharmacol Sci 1989; 10: 442-447
• 16 Seamon KB, Daly JW. Forskolin, cyclic AMP and cellular physiology. Trends Pharmacol Sci 1983; 4: 120-123
• 17 Tranquille N, Emeis JJ. The involvement of products of the phospholipase pathway in the acute release of tissue-type plasminogen activator.from perfused rat hindlegs. Eur J Pharmacol 1992; 213: 285-292
• 18 Komas N, Lugnier C, Stocklet J-C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 1991; 104: 495-503
• 19 Emeis JJ. Mechanisms involved in short-term changes in blood levels of tissue-type plasminogen activator. In Tissue-type Plasminogen Activator, Physiological and Clinical Aspects. Kluft C. (ed). CRC Press; Boca Raton, FL: 1988. 2 21-35
• 20 Klöcking H-P, Hoffmann A. Inhibition of thrombin-induced tissue-type plasminogen activator release by agents which increase intracellular cyclic AMP. Thromb Res 1990; 59: 789-792
• 21 Evans HG, Smith JA, Lewis MJ. Release of endothelium-derived relaxing factor is inhibited by 8-bromo-cyclic guanosine monophosphate. J Cardiovasc Pharmacol 1988; 12: 672-677
• 22 Hogan JC, Smith JA, Richards AC, Lewis MJ. Atrial natriuretic peptide inhibits the release of endothelium-derived relaxing factor from blood vessels of the rabbit. Eur J Pharmacol 1989; 165: 129-134
• 23 Doni MG, Whittle BJR, Palmer RMJ, Moncada S. Actions of nitric acid on the release of prostacyclin from bovine endothelial cells in culture. Eur J Pharmacol 1988; 151: 19-25
• 24 Kato J, Lanier-Smith KL, Currie MG. Cyclic GMP down-regulates atrial natriuretic peptide receptors on cultured vascular endothelial cells. J Biol Chem 1991; 266: 14681-14685
• 25 Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3',5'-monophosphate. Hypertension 1992; 19: 320-325
• 26 Drummer C, Lüdke S, Spannagl M, Schramm W, Gerzer R. The nitric oxide donor SIN-1 is a potent inhibitor of plasminogen activator inhibitor release from stimulated platelets. Thromb Res 1991; 63: 553-556